US Senate panel to weigh Novo Nordisk subpoena over Ozempic, Wegovy prices By Reuters


© Reuters. FILE PHOTO: Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams/File Photo/File Photo

WASHINGTON (Reuters) – The U.S. Senate health panel said on Tuesday it would vote later this month on whether to subpoena Novo Nordisk (NYSE:) over the high U.S. prices for weight loss drugs Ozempic and Wegovy compared to those offered in other countries.

The Senate Committee on Health, Education, Labor, and Pensions, which is investigating the drugs’ costs, will weigh a subpoena for senior Novo Nordisk Inc executive Doug Langa when it meets on June 18, it said in a statement.

Source link

Leave A Reply

Your email address will not be published.